Congresswoman Harshbarger on US Pharmaceutical Dependence on China

US Pharmaceutical Reliance on China

• 💊 Congresswoman Diana Harshbarger, a pharmacist, highlights that China controls 90% of the Active Pharmaceutical Ingredients (APIs) market.
• ⚠️ This reliance means the U.S. is effectively held hostage by China for critical prescription drugs like ibuprofen and antibiotics.
• 🎯 China's cornering of the market was not accidental; they lowered prices to gain control.

Strategies to Reduce Dependence

• 🇺🇸 Harshbarger supports President Trump's pressure on China, including the potential implementation of tariffs on pharmaceuticals.
• 💡 She advocates for incentivizing companies to manufacture drugs in America, potentially through tax decreases.
• 🤝 A proposed solution involves leveraging the Abraham Accords to diversify supply chains by partnering with allied nations like Israel and the UAE.

The Abraham Accords Cooperation and Security Act

• 📜 Harshbarger has introduced a bill to establish an FDA technical assistance facility in Israel.
• 🚀 This initiative aims to streamline the process for getting products to market, saving time and money by avoiding redundant FDA reviews.
• 🌍 The goal is to create a hub in the Middle East to strengthen allied nations and push back against China's influence.

Challenges and Incentives

• 📉 Research suggests tariffs might incentivize U.S. manufacturing of brand-name drugs, but not older, off-patent generics which represent a large volume.
• 🏭 There's a risk that companies might close manufacturing facilities if they can't profit from older generics, which are still critical.
• 📍 A starting point could be supporting existing U.S. manufacturers, such as the only penicillin plant in the country, located in Harshbarger's district, by securing contracts for domestic production.